Cytogenetic testing for therapeutic indication in cancer.
The association of cytogenetic abnormalities with cancer is well established. However, due to the historic lack of specific insight into the functional role of these anomalies, they have mostly served as diagnostic and/or prognostic indicators. Recent developments in chronic myelogenous leukemia and breast cancer have raised hopes for specific cytogenetic alterations to serve as therapeutic targets. This article reviews the aid provided by molecular diagnostics in these exciting developments in the cancer arena.
Mundle
Suneel
S
Rush University Medical Center, Department of Biochemistry, Naperville, Chicago, IL 60565, USA. smundle@rush.edu
Noskina
Yelina
Y
D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy